SG11202005896WA - Esketamine for the treatment of depression - Google Patents
Esketamine for the treatment of depressionInfo
- Publication number
- SG11202005896WA SG11202005896WA SG11202005896WA SG11202005896WA SG11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA
- Authority
- SG
- Singapore
- Prior art keywords
- esketamine
- depression
- treatment
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 229960000450 esketamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609504P | 2017-12-22 | 2017-12-22 | |
| US201862663206P | 2018-04-26 | 2018-04-26 | |
| US201862663219P | 2018-04-26 | 2018-04-26 | |
| US201862667406P | 2018-05-04 | 2018-05-04 | |
| US201862675846P | 2018-05-24 | 2018-05-24 | |
| US201862755905P | 2018-11-05 | 2018-11-05 | |
| PCT/US2018/066143 WO2019126108A1 (en) | 2017-12-22 | 2018-12-18 | Esketamine for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005896WA true SG11202005896WA (en) | 2020-07-29 |
Family
ID=65003585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005896WA SG11202005896WA (en) | 2017-12-22 | 2018-12-18 | Esketamine for the treatment of depression |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707440B2 (en) |
| EP (1) | EP3501542A1 (en) |
| JP (2) | JP2021506924A (en) |
| KR (2) | KR20200113197A (en) |
| CN (2) | CN117531017A (en) |
| AU (2) | AU2018282466A1 (en) |
| BR (1) | BR112020012473A2 (en) |
| CA (1) | CA3086478A1 (en) |
| IL (1) | IL275482A (en) |
| JO (1) | JOP20200156A1 (en) |
| MA (1) | MA47719A (en) |
| MX (2) | MX2020006650A (en) |
| PH (1) | PH12020500555A1 (en) |
| SG (1) | SG11202005896WA (en) |
| TW (2) | TW202415363A (en) |
| WO (1) | WO2019126108A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX371392B (en) | 2013-03-15 | 2020-01-28 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride. |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| IL278759B1 (en) | 2018-06-27 | 2024-08-01 | Clexio Biosciences Ltd | Method of treating major depressive disorder |
| CA3113198A1 (en) | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| AU2020231172A1 (en) * | 2019-03-05 | 2021-09-23 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| CA3133012A1 (en) * | 2019-08-05 | 2021-02-11 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| CN114286674A (en) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | Esketamine for use in the treatment of patients with major depressive disorder including suicidal ideation |
| CN115135363A (en) * | 2019-09-13 | 2022-09-30 | 杨森制药公司 | Intranasal administration of esketamine |
| TW202135787A (en) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | Esketamine formulations and methods for preparation and storage |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| WO2021137148A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| CN116635941A (en) * | 2020-10-22 | 2023-08-22 | 通尼克斯医药控股公司 | Randomization compliance method for assessing the importance of intervention on disease outcome |
| WO2024201274A1 (en) * | 2023-03-24 | 2024-10-03 | Janssen Pharmaceutica Nv | Esketamine for use in the treatment of depression |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10025A (en) | 1853-09-20 | Improvement in turbines | ||
| CH535201A (en) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Process for the resolution of racemic 2- (o-chlorophenyl) -2-methylaminocyclohexanone into the optically active isomers |
| JPS632932A (en) | 1986-06-23 | 1988-01-07 | Teijin Ltd | Powdery composition for nasal administration |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| DE4312016A1 (en) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stable ketamine solutions |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| JP4173538B2 (en) | 1995-02-24 | 2008-10-29 | スチュアート エル ウェグ | Nasal and ophthalmic administration of ketamine for pain management and detoxification |
| CA2230690C (en) | 1995-08-30 | 2008-12-23 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| FR2739294B1 (en) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | NASAL SAFETY TIP |
| DE19619665C2 (en) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemate separation of ketamine |
| DE19723133A1 (en) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Discharge device for media |
| FR2764807B1 (en) | 1997-06-18 | 1999-08-20 | Valois Sa | NASAL DISPENSING DEVICE FOR A FLUID OR POWDERY PRODUCT |
| JP4790123B2 (en) | 1998-07-24 | 2011-10-12 | ヨー、セオ、ホン | Dispensing clear aqueous solution with bile acid |
| US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| EP1103256A1 (en) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome |
| AU2001291159A1 (en) | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| CA2529857A1 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US20040248964A1 (en) | 2002-11-18 | 2004-12-09 | Crooks Peter A. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
| US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
| DK1885414T3 (en) | 2005-06-01 | 2013-02-11 | Shl Group Ab | DEVICE FOR THE DELIVERY OF A MEDICINE |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| US8785500B2 (en) | 2006-03-22 | 2014-07-22 | Icahn School Of Medicine At Mount Sinai | Intranasal administration of ketamine to treat depression |
| US20070256688A1 (en) | 2006-04-21 | 2007-11-08 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
| AU2007253684A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| DE102007009888A1 (en) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder |
| WO2008151179A2 (en) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| CN103108631B (en) | 2010-06-15 | 2015-08-26 | 格吕伦塔尔有限公司 | Be used for the treatment of the combination medicine of pain |
| US9073819B2 (en) | 2011-06-30 | 2015-07-07 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| CN109793725B (en) | 2011-10-14 | 2023-07-25 | 美国政府健康及人类服务部 | Pharmaceutical composition for treating melancholia and neuropathic pain and application thereof |
| CN104053785A (en) | 2011-11-14 | 2014-09-17 | 综合医院公司 | Assays For Selecting A Treatment Regimen For A Subject With Depression And Methods For Treatment |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2830604A4 (en) | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | Compositions comprising scopolamine and ketamine in the treatment of depression |
| WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| JP6722453B2 (en) | 2012-08-23 | 2020-07-15 | スチュアート エル ウェグ | Anxiolytic composition, formulation and method of use |
| FR2994844B1 (en) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | GELIFYING FORMULATION BASED ON KETAMINE |
| NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
| ES2484068B1 (en) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | A pharmaceutical composition containing ketamine and amitriptyline |
| ES2760251T3 (en) | 2013-04-12 | 2020-05-13 | Icahn School Med Mount Sinai | Method for treating post-traumatic stress disorder |
| EP3960162A1 (en) | 2013-08-26 | 2022-03-02 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| ES2897453T3 (en) | 2013-09-13 | 2022-03-01 | Univ Chiba Nat Univ Corp | Application of R-ketamine and salt thereof as pharmaceuticals |
| CN103705909A (en) | 2013-12-16 | 2014-04-09 | 陈镜伊 | Drug for painless induced abortion |
| WO2015101693A1 (en) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Combined preparations and compositions for the treatment of oropharyngeal pain |
| EP3094312B1 (en) | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| EP4180030A1 (en) | 2014-04-17 | 2023-05-17 | Ketabon GmbH | Oral dosage form of ketamine |
| MX2016013787A (en) | 2014-05-04 | 2017-07-24 | Firmenich & Cie | Flavored food and beverage products. |
| FR3023188B1 (en) | 2014-07-04 | 2016-08-19 | Aptar France Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
| AU2015301782B2 (en) * | 2014-08-13 | 2020-09-03 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| EP3240422A1 (en) | 2014-12-31 | 2017-11-08 | Icahn School of Medicine at Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
| CN104798728A (en) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | Creation method and applications of postpartum depression animal models |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
| US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
-
2018
- 2018-12-18 SG SG11202005896WA patent/SG11202005896WA/en unknown
- 2018-12-18 MX MX2020006650A patent/MX2020006650A/en unknown
- 2018-12-18 KR KR1020207021196A patent/KR20200113197A/en not_active Application Discontinuation
- 2018-12-18 CN CN202311355796.8A patent/CN117531017A/en active Pending
- 2018-12-18 KR KR1020247000937A patent/KR20240011237A/en not_active Application Discontinuation
- 2018-12-18 US US16/956,403 patent/US11707440B2/en active Active
- 2018-12-18 JO JOP/2020/0156A patent/JOP20200156A1/en unknown
- 2018-12-18 JP JP2020534520A patent/JP2021506924A/en active Pending
- 2018-12-18 CA CA3086478A patent/CA3086478A1/en active Pending
- 2018-12-18 WO PCT/US2018/066143 patent/WO2019126108A1/en active Application Filing
- 2018-12-18 BR BR112020012473-7A patent/BR112020012473A2/en unknown
- 2018-12-18 CN CN201880090058.6A patent/CN112423789A/en active Pending
- 2018-12-21 TW TW112130258A patent/TW202415363A/en unknown
- 2018-12-21 AU AU2018282466A patent/AU2018282466A1/en not_active Abandoned
- 2018-12-21 MA MA047719A patent/MA47719A/en unknown
- 2018-12-21 TW TW107146335A patent/TWI843711B/en active
- 2018-12-21 EP EP18215651.3A patent/EP3501542A1/en active Pending
-
2020
- 2020-06-18 IL IL275482A patent/IL275482A/en unknown
- 2020-06-18 PH PH12020500555A patent/PH12020500555A1/en unknown
- 2020-07-13 MX MX2023012450A patent/MX2023012450A/en unknown
-
2023
- 2023-07-05 US US18/347,393 patent/US20240000728A1/en active Pending
- 2023-10-06 JP JP2023174444A patent/JP2024001204A/en active Pending
-
2024
- 2024-10-17 AU AU2024227438A patent/AU2024227438A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240000728A1 (en) | 2024-01-04 |
| MA47719A (en) | 2020-01-15 |
| CN112423789A (en) | 2021-02-26 |
| US20210386688A1 (en) | 2021-12-16 |
| CA3086478A1 (en) | 2019-06-27 |
| TW201940162A (en) | 2019-10-16 |
| US11707440B2 (en) | 2023-07-25 |
| KR20240011237A (en) | 2024-01-25 |
| WO2019126108A1 (en) | 2019-06-27 |
| JOP20200156A1 (en) | 2022-10-30 |
| AU2024227438A1 (en) | 2024-11-07 |
| KR20200113197A (en) | 2020-10-06 |
| RU2020123893A (en) | 2022-01-24 |
| RU2020123893A3 (en) | 2022-04-29 |
| IL275482A (en) | 2020-08-31 |
| PH12020500555A1 (en) | 2021-05-17 |
| JP2024001204A (en) | 2024-01-09 |
| MX2023012450A (en) | 2023-10-31 |
| MX2020006650A (en) | 2020-11-06 |
| EP3501542A1 (en) | 2019-06-26 |
| TW202415363A (en) | 2024-04-16 |
| AU2018282466A1 (en) | 2019-07-11 |
| JP2021506924A (en) | 2021-02-22 |
| CN117531017A (en) | 2024-02-09 |
| BR112020012473A2 (en) | 2020-11-24 |
| TWI843711B (en) | 2024-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Esketamine for the treatment of depression | |
| IL279627A (en) | Method for the treatment of depression | |
| IL269371A (en) | Treatment methods | |
| GB201707153D0 (en) | Therapy | |
| GB201608885D0 (en) | Treatment | |
| IL283948A (en) | Methods for the treatment of depression | |
| HK1258276A1 (en) | Compounds and combinations for the treatment of hiv | |
| GB201813876D0 (en) | Treatment | |
| GB201719646D0 (en) | Therapy | |
| GB201708663D0 (en) | Therapy | |
| IL286000A (en) | Esketamine for the treatment of depression | |
| GB201813986D0 (en) | Coffins | |
| HK1257272A1 (en) | Means for the treatment of hiv | |
| HK1247558A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| GB201800546D0 (en) | Treatment | |
| PL3484475T3 (en) | 1-methylnicotinamide for the treatment of cardiovascular disease | |
| PL3448340T3 (en) | Application aid for the treatment of wounds | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| IL272658A (en) | Surface treatment | |
| ZA201906319B (en) | Methods of treating depression | |
| GB201718985D0 (en) | Treatment | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| GB201814905D0 (en) | Treatment | |
| GB201713650D0 (en) | Treatment | |
| GB201706955D0 (en) | Treatment |